EGFR and cervical squamous cell carcinoma: Sapitinib (EGFR/HER2 inhibitor) was specific for HNSC and cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), and lung squamous cell carcinoma (LUSC) (Fig. 6f).